Search Results - "Nos, P"

Identification of serum and tissue micro‐RNA expression profiles in different stages of inflammatory bowel disease by Iborra, M., Bernuzzi, F., Correale, C., Vetrano, S., Fiorino, G., Beltrán, B., Marabita, F., Locati, M., Spinelli, A., Nos, P., Invernizzi, P., Danese, S.

“…Summary The altered expression of micro‐RNA (miRNA) has been associated with Crohn's disease (CD) and ulcerative colitis (UC). The aim of this study was to…”
Get full text

Impact of Anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship with de novo intestinal bowel disease in multiple sclerosis: a review by Quesada-Simó, A, Garrido-Marín, A, Nos, P, Gil-Perotín, S

“…Multiple sclerosis (MS) and inflammatory bowel disease (IBD) are autoimmune disorders characterized by inflammatory episodes affecting the brain and the…”
Get full text

Letter: management of post‐operative Crohn's disease ‐ thiopurines vs adalimumab by Aguas, M., Nos, P., Gisbert, J. P.

Get full text

Collusive induction in perverse relating: perverse enactments and bastions as a camouflage for death anxiety by Nos, Jaime P

“…The author argues that one of the main functions of perverse relatedness is to induce the analyst into becoming the patient's unconscious accomplice in a…”
Get more information

Alpha‐defensins (α‐Defs) in Crohn's disease: decrease of ileal α‐Def 5 via permanent methylation and increase in plasma α‐Def 1‐3 concentrations offering biomarker utility by Cerrillo, E., Moret, I., Iborra, M., Ramos, D., Busó, E., Tortosa, L., Sáez‐González, E., Nos, P., Beltrán, B.

“…Summary An impaired expression of α‐defensins (α‐Defs) in the ileal mucosa and, conversely, increased levels in plasma, have been reported in Crohn's disease…”
Get full text

Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era by NUNES, T, ETCHEVERS, M. J, ESTEVE, M, TAXONERA SAMSO, C, MONTORO HUGUET, M, GISBERT, J. P, MARTIN ARRANZ, M. D, GARCIA-SEPULCRE, M. F, BARREIRO- DE ACOSTA, M, BELTRAN, B, ALCAIDE SUAREZ, N, SARO GISMERA, C, DOMENECH, E, CABRIADA, J. L, CANAS-VENTURA, A, GOMOLLON, F, PANES, J, GARCIA-SANCHEZ, V, BER, Y, PENALVA, M, MERINO, O, NOS, P, GARCIA-PLANELLA, E, CASBAS, A. G

“…Recently, the notion that smoking may adversely affect Crohn's disease (CD) outcomes has been challenged by the suggestion that the widespread use of…”
Get full text

Use of telemedicine in inflammatory bowel disease: a real monitoring option? by Aguas, M, Del Hoyo, J, Faubel, R, Nos, P

Get more information

Incidence, risk factors and clinical course of thiopurine‐induced liver injury in patients with inflammatory bowel disease by BASTIDA, G., NOS, P., AGUAS, M., BELTRÁN, B., RUBÍN, Á., DASÍ, F., PONCE, J.

“…Summary Background : The incidence of thiopurine‐induced hepatotoxicity in patients with inflammatory bowel disease varies in different studies. Aims : To…”
Get full text

Long‐term durability of response to adalimumab in Crohn's disease by Chaparro, M., Panés, J., García, V., Merino, O., Nos, P., Domènech, E., Peñalva, M., García‐Planella, E., Esteve, M., Hinojosa, J., Andreu, M., Muñoz, F., Gutiérrez, A., Mendoza, J.L., Barrio, J., Barreiro‐de, M., Vera, I., Vilar, P., Cabriada, J.L., Montoro, M.A., Aldeguer, X., Saro, C., Gisbert, J.P.

“…Background: Adalimumab is an effective treatment for Crohn's disease (CD), but may also be associated with loss of response. Few reports provide insight into…”
Get full text

Idiopathic acute pancreatitis in patients with inflammatory bowel disease: a multicentric cohort study by García García de Paredes, A., Rodríguez-Escaja, C., Iborra, M., Algaba, A., Cameo, J.I., de la Peña, L., Gomollón, F., Van Domselaar, M., Busta, R., Rodríguez de Santiago, E., Castaño García, A., del Val, A., Bermejo, F., Gutiérrez, A., Guardiola, J., Mesonero, F., Riestra, S., Nos, P., Albillos, A., López-Sanromán, A.

Get full text

Clinical outcome of newly diagnosed Crohn’s disease: a comparative, retrospective study before and after infliximab availability by DOMÈNECH, E., ZABANA, Y., GARCIA‐PLANELLA, E., LÓPEZ SAN ROMÁN, A., NOS, P., GINARD, D., GORDILLO, J., MARTÍNEZ‐SILVA, F., BELTRÁN, B., MAÑOSA, M., CABRÉ, E., GASSULL, M. A.

“…Summary Background  Infliximab (IFX) could change the course of Crohn’s disease (CD) by reducing steroid use, surgery or prompting earlier introduction of…”
Get full text

Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? by DOMÈNECH, E., HINOJOSA, J., NOS, P., GARCIA‐PLANELLA, E., CABRÉ, E., BERNAL, I., GASSULL, M. A.

“…Summary Background:  Few data are available regarding the evolution of Crohn's disease after discontinuing a successful course of infliximab. Aim:  To evaluate…”
Get full text

Safe and effective application of anti-TNF-α in a patient infected with HIV and concomitant Crohn’s disease by Beltrán, B, Nos, P, Bastida, G, Iborra, M, Hoyos, M, Ponce, J

Get full text

Healthcare seeking for constipation: a population‐based survey in the Mediterranean area of Spain by GÁLVEZ, C., GARRIGUES, V., ORTIZ, V., PONCE, M., NOS, P., PONCE, J.

“…Summary Background The use of healthcare resources for the management of constipation is not well‐known. Aim To analyse healthcare seeking for constipation,…”
Get full text

Factors predicting severity of acute pancreatitis: A prospective cohort study by del Val, A, Díaz, F.C, Sáez, E, Alvarez de Sotomayor, D, Tenías, J.M, Ortuño, J.A, Higón, M.D, Nos, P

Get full text

Disease severity in familial cases of IBD by Andreu, M., Márquez, L., Domènech, E., Gisbert, J.P., García, V., Marín-Jiménez, I., Peñalva, M., Gomollón, F., Calvet, X., Merino, O., Garcia-Planella, E., Vázquez-Romero, N., Esteve, M., Nos, P., Gutiérrez, A., Vera, I., Cabriada, J.L., Martín, M.D., Cañas-Ventura, A., Panés, J.

“…Phenotypic traits of familial IBD relative to sporadic cases are controversial, probably related to limited statistical power of published evidence. To know if…”
Get full text

P365 Serum adalimumab levels predict successful remission and safe de-intensification in inflammatory bowel disease patients in clinical practice by Aguas, M., Bosό, V., Navarro, B., Marqués-Miñana, M.R., Bastida, G., Beltrán, B., Iborra, M., Monte-Boquet, E., Poveda-Andrés, J.L., Nos, P.

Get full text

Accuracy of magnetic resonance enterography in the preoperative assessment of patients with Crohn's disease of the small bowel by Pous‐Serrano, S., Frasson, M., Palasí Giménez, R., Sanchez‐Jordá, G., Pamies‐Guilabert, J., Llavador Ros, M., Nos Mateu, P., Garcia‐Granero, E.

“…Aim To assess the accuracy of magnetic resonance enterography in predicting the extension, location and characteristics of the small bowel segments affected by…”
Get full text

P650 Optimization through iv maintenance with ustekinumab in Inflammatory Bowel Disease. Efficacy and adjusted regimen in real world by Mínguez, A, Coello, E, Gomez, M, Ripoll, P, Garrido, A, Aguas, M, Iborra, M, Cerrillo, E, Tortosa, L, Bayarri, V, Nos, P, Bastida, G

“…Abstract Background Ustekinumab (UST) is an effective treatment for Crohn's disease (CD) and ulcerative colitis (UC). However, some patients do not respond to…”
Get full text

Real‐world short‐term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry by Iborra, M., Beltrán, B., Fernández‐Clotet, A., Gutiérrez, A., Antolín, B., Huguet, J.M., De Francisco, R., Merino, O., Carpio, D., García‐López, S., Mesonero, F., Navarro, P., Ferreiro‐Iglesias, R., Carbajo, A.Y., Rivero, M., Gisbert, J.P., Piñero‐Pérez, M.C., Monfort, D., Bujanda, L., García‐Sepulcre, M.F., Martín‐Cardona, A., Cañete, F., Taxonera, C., Domènech, E., Nos, P., Sierra‐Ausín, M., Ferrer‐Rosique, J.A., Martín‐Arranz, M.D., González‐Muñoza, C., Manceñido, N., Rodriguez‐Lago, I., Benítez, J.M., Forés‐Bosch, A., Navarro‐Llavat, M., Calafat, M., Madrigal‐Domínguez, R.E., Arroyo, M., Busquets, D., Lorente, R., Sainz‐Arnau, E., Hernández‐Camba, A., Morales‐Alvarado, V.J., Paredes, J.M., Van Domselaar, M., Hervás, D., Cañada‐Martínez, A., Castro‐Poceiro, J., Cameo‐Lorenzo, J., Fernández‐Salazar, L., Riestra, S., Casas‐Deza, D., Tosca, J., Barrio, J., García, M.J., Chaparro, M.

“…Summary Background There are limited data of ustekinumab administered according to the doses recommended in the UNITI studies. Aim To assess the real‐world,…”
Get full text